Novavax

Novavax Inc. will submit a request to the U.S. Food and Drug Administration to authorize the company’s COVID-19 vaccine in January 2022, further delaying the submission it had expected by the end of 2021.

Novavax

Novavax Inc.’s Covid-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on December 22, suggesting that the U.S. drugmaker’s existing Covid-19 vaccine can help combat the new Omicron variant.

Novavax

The European Union on December 20 approved the use of Novavax’s COVID-19 vaccine in people 18 years and older, giving a boost to the U.S. biotech after long delays and paving the way for a fifth shot in the EU as the Omicron variant spreads quickly.

Novavax

Novavax Inc. said on Thursday the company could begin commercial manufacturing of a Covid-19 vaccine tailored for the Omicron coronavirus variant in January 2022, while testing whether or not its current vaccine works against the variant.

Novavax

Novavax Inc. said on November 26 the company had started working on a version of a COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.

Novavax

Vaccine developer Novavax Inc. said on Nov. 4 that the company completed the submission process for emergency use listing of the Covid-19 vaccine candidate NVX-CoV2373 with the World Health Organization.

Novavax

Novavax Inc. and partner Serum Institute of India said on November 1 they received emergency use authorization for their Covid-19 vaccine in Indonesia, making it the first approval anywhere in the world for Novavax.

Novavax

Novavax Inc. said on Oct. 27 the company had completed the real-time submission of an application for the authorization of the Covid-19 vaccine candidate NVX-CoV2373 in the United Kingdom.

Novavax

Shares of Novavax Inc. fell 16 percent after a report from Politico said the company faces significant hurdles in proving it can manufacture the experimental Covid-19 vaccine NVX-CoV2373 that meets regulators’ quality standards, resulting in production delays.

Novavax

Vaccine developer Novavax Inc. said on Sept. 10 at least 2 billion doses of the company’s Covid-19 vaccine would be available in 2022.